Company Of The Day: Roche Holdings
What?
Roche Holdings (OTCMKTS: RHHBY) Q3 2022 revenue declined 6% to CHF 14.74 billion ($14.8 billion).
Why?
Relevant Articles
- A 3x Expected Rise In Mounjaro Sales Is Likely To Drive Eli Lilly’s Q1
- What Should You Do With Danaher Stock At $250 After Q1 Beat?
- Will A Macau Recovery Drive MGM Stock Higher Following Q1 Results?
- Lockheed Martin Stock Will Likely Remain In Focus After A Stellar Q1
- Up 17% YTD, What To Expect From eBay Q1 Results?
- Rising 21% This Year, What Lies Ahead For Exxon Stock Following Q1 Earnings?
A decline in demand for Covid-19 diagnostics and treatments outweighed the gains that the company made with its hemophilia and multiple sclerosis drugs.
So What?
Roche stock was down by almost 1.5% in early trading on Tuesday although it recovered later in the day.
See Our Complete Analysis For Roche
| Returns | Oct 2022 MTD [1] |
2022 YTD [1] |
2017-22 Total [2] |
| RHHBY Return | 1% | -20% | 44% |
| S&P 500 Return | 4% | -22% | 66% |
| Trefis Multi-Strategy Portfolio | 3% | -24% | 201% |
[1] Month-to-date and year-to-date as of 10/19/2022
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates
See all Trefis Price Estimates